Target intelligence / Profile preview

Protein sel-1 homolog 2 (SEL1L2)

Target
SEL1L2
Molecular classification
Other (ERAD adaptor protein), Accessory subunit of ER membrane E3 ubiquitin ligase complex
01

Overview

SEL1L2 is an adaptor protein that participates in the endoplasmic reticulum-associated degradation (ERAD) pathway by linking the E3 ubiquitin ligase SYVN1 (HRD1) complex to misfolded cargo proteins destined for proteasomal degradation[1][3][5]. It is evolutionarily related to SEL1L and shares structural features, but SEL1L2 is less well characterized, with its specific protein-protein interactions, tissue distribution, and functional importance remaining subjects for future research[1][3][5]. The ERAD pathway regulates ER protein quality, contributing to cellular homeostasis and response to stress; in this machinery, SEL1L2 is thought to help scaffold the degradation process but has not been directly linked to disease pathology or targeted therapies[1][2].

Other names
SEL1L2C20orf50Sel-1L2DKFZp434C1826suppressor of lin-12-like protein 2protein sel-1 homolog 2SEL1L2 adaptor subunit of ERAD E3 ligasesel-1 suppressor of lin-12-like 2
02

Mechanism of action

Not applicable; drugs do not directly target SEL1L2. General ERAD modulation occurs through E3 ligase inhibition or proteasome inhibition[2][4].

03

Biological functions

ER-associated degradation (ERAD), contributing to quality control by facilitating the removal of misfolded secretory and membrane proteins from the ER for proteasomal degradation
04

Disease associations

Associated with congenital disorders such as meningocele and parietal foraminaNo strong direct evidence for implication in major complex diseases (e.g., cancer, neurodegeneration)
05

Safety considerations

None directly attributed to SEL1L2. General safety concerns for ERAD modulation include potential disruption of protein quality control, leading to ER stress and proteotoxicity[2][4].
06

Interacting drugs

None documented. There are no known drugs directly targeting SEL1L2; drugs affecting ERAD generally act via upstream sensors, chaperones, or E3 ligase components[1][2][4].
07

Biomarkers

None established for SEL1L2[1][2].

Beyond the preview

Go deeper on Protein sel-1 homolog 2 (SEL1L2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protein sel-1 homolog 2 (SEL1L2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call